Impact of COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study

被引：0
|
作者：
Autore, Francesco
Visentin, Andrea
Deodato, Marina
Vitale, Candida
Galli, Eugenio
Fresa, Alberto
Fazzi, Rita
Sanna, Alessandro
Olivieri, Jacopo
Scortechini, Ilaria
del Principe, Maria Ilaria
Sportoletti, Paolo
Schiattone, Luana
Maschio, Nilla
Facchinelli, Davide
Coscia, Marta
Tedeschi, Alessandra
Trentin, Livio
Innocenti, Idanna
Candoni, Anna
Busca, Alessandro
Pagano, Livio
Laurenti, Luca
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1552495
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [21] A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Cartron, Guillaume
    Cazin, Bruno
    Coiffier, Bertrand
    Lepretre, Stephane
    Feugier, Pierre
    Aurran, Therese
    Chartier, Guylene
    Sadoun, Alain
    Ribrag, Vincent
    BLOOD, 2010, 116 (21) : 1015 - 1016
  • [22] Orphan-drug status granted to new anti-CD20 monoclonal antibody for chronic lymphocytic leukemia
    不详
    IMMUNOTHERAPY, 2010, 2 (01) : 7 - 7
  • [23] Orphan-drug status granted to new anti-CD20 monoclonal antibody for chronic lymphocytic leukemia
    不详
    FUTURE ONCOLOGY, 2010, 6 (01) : 10 - 10
  • [24] THE COURSE OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH SJOGREN'S SYNDROME TREATED WITH ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB)
    Sokol, E.
    Torgashina, A.
    Chalcev, B.
    Khvan, J.
    Golovina, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 896 - 897
  • [25] Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy
    Eeva Feuth
    Valtteri Nieminen
    Antti Palomäki
    Juha Ranti
    Marcus Sucksdorff
    Taru Finnilä
    Jarmo Oksi
    Tytti Vuorinen
    Thijs Feuth
    European Journal of Clinical Microbiology & Infectious Diseases, 2024, 43 : 723 - 734
  • [26] Antibody-dependent cellular phagocytosis is responsible for efficacy of anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia
    Chu, Charles C.
    VanDerMeid, Karl R.
    Elliott, Michael Rusty
    Baran, Andrea M.
    Barr, Paul M.
    Zent, Clive S.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [27] Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy
    Feuth, Eeva
    Nieminen, Valtteri
    Palomaeki, Antti
    Ranti, Juha
    Sucksdorff, Marcus
    Finnilae, Taru
    Oksi, Jarmo
    Vuorinen, Tytti
    Feuth, Thijs
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (04) : 723 - 734
  • [28] Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
    Zelenetz, Andrew David
    Mato, Anthony R.
    Robak, Tadeusz
    Jones, Jeffrey Alan
    Pagel, John M.
    Barrientos, Jacqueline Claudia
    Brown, Jennifer R.
    Montillo, Marco
    Kipps, Thomas J.
    Dubowy, Ronald
    Xing, Guan
    Li, Julia
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 285B - 285B
  • [30] CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Stasilojc, Grzegorz
    Felberg, Anna
    Taszner, Michal
    Urban, Aleksandra
    Ma, Shuo
    Blom, Anna
    Lundin, Jeanette
    Osterborg, Anders
    Okroj, Marcin
    MOLECULAR IMMUNOLOGY, 2019, 114 : 415 - 415
12345